Ribociclib succinate hydrate (LEE011; LEE-011; NVP-LEE-011; NVP-LEE011; Kisqali), the succinate salt and hydrated form of Ribociclib, is a potent inhibitor of CDK4/6 (cyclin-dependent kinase) (IC50s = 10 nM and 39 nM) approved in March 2017 by FDA for the treatment of breast cancer.

AZD5438 (AZD-5438; AZD 5438) is a novel, potent and selective small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with potential antineoplastic activity.

NG 52 (NG-52), a tri-substituted purine, is a cell-permeable, reversible, and ATP-competitve inhibitor of the cell cycle-regulating kinase, Cdc28p with IC50 of 7 μM, and the related Pho85p kinase with IC50 of 2 μM.

PHA-767491 HCl (formerly known as CAY10572 HCl) is a novel potent ATP-competitive and dual CDC7/CDK9 inhibitor with IC50 of 10 nM and 34 nM in cell-free assays, respectively.

Atuveciclib racemate (formerly BAY-1143572 racemate) is the racemic mixture of Atuveciclib, which is novel, potent, oral and highly selective PTEFb/CDK9 inhibitor currently in Phase I clinical trial to treat cancer.

AZD4573 (AZD-4573) is a novel, potent and short acting inhibitor of serine/threonine CDK9 (cyclin-dependent kinase 9, IC50<0.004 μM) with potential anticancer activities.

Dalpiciclib (also known as SHR-6390) is a novel,highly selective, orally bioavailable CDK4/6 inhibitor with anticancer acivity.

Prexasertib mesylate hydrate (also known as LY2606368 mesylate hydrate) is the hydrated mesylate salt of Prexasertib with potential anticancer activity.

Kenpaullone (NSC-664704) is a novel, potent and ATP competitive inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively.

Purvalanol A (NG60; NG-60; NG 60) is a potent and cell-permeable CDK (cyclin-dependent kinase) inhibitor with potential antitumor activity.